CN116286734A - Mutant of wild LbCAs12a protein and SNP detection application - Google Patents
Mutant of wild LbCAs12a protein and SNP detection application Download PDFInfo
- Publication number
- CN116286734A CN116286734A CN202211514174.0A CN202211514174A CN116286734A CN 116286734 A CN116286734 A CN 116286734A CN 202211514174 A CN202211514174 A CN 202211514174A CN 116286734 A CN116286734 A CN 116286734A
- Authority
- CN
- China
- Prior art keywords
- mutant
- wild
- protein
- lbcas12a
- crrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 70
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 44
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 44
- 230000035772 mutation Effects 0.000 claims abstract description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 12
- 235000018102 proteins Nutrition 0.000 claims description 40
- 108020004414 DNA Proteins 0.000 claims description 19
- 230000008685 targeting Effects 0.000 claims description 17
- 102000053602 DNA Human genes 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 108091033409 CRISPR Proteins 0.000 claims description 8
- 238000010354 CRISPR gene editing Methods 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 108020005004 Guide RNA Proteins 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 235000004252 protein component Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 238000012864 cross contamination Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 108700028369 Alleles Proteins 0.000 description 27
- 229920002401 polyacrylamide Polymers 0.000 description 27
- 208000000415 potassium-aggravated myotonia Diseases 0.000 description 26
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 23
- 239000000758 substrate Substances 0.000 description 23
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 22
- 238000003776 cleavage reaction Methods 0.000 description 19
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 18
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 13
- 108700004991 Cas12a Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000002974 pharmacogenomic effect Effects 0.000 description 5
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 5
- 229960005080 warfarin Drugs 0.000 description 5
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 4
- 229960003009 clopidogrel Drugs 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 238000007397 LAMP assay Methods 0.000 description 3
- 230000036267 drug metabolism Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 101150098304 cas13a gene Proteins 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- GZZDPOCSWMTUJU-ODAXIEOESA-N (2s)-2-[(3e)-3-(carboxymethylidene)-4-sulfanylpiperidin-1-yl]-2-(2-chlorophenyl)acetic acid Chemical compound C1CC(S)C(=C/C(=O)O)/CN1[C@H](C(O)=O)C1=CC=CC=C1Cl GZZDPOCSWMTUJU-ODAXIEOESA-N 0.000 description 1
- 101100385358 Alicyclobacillus acidoterrestris (strain ATCC 49025 / DSM 3922 / CIP 106132 / NCIMB 13137 / GD3B) cas12b gene Proteins 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102100031437 Cell cycle checkpoint protein RAD1 Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101001130384 Homo sapiens Cell cycle checkpoint protein RAD1 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 101150059443 cas12a gene Proteins 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 108010012052 cytochrome P-450 CYP2C subfamily Proteins 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- -1 sinbocmod Chemical compound 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The application discloses a mutant of a wild type LbCAs12a protein and SNP detection application thereof, wherein the amino acid sequence of the wild type LbCAs12a protein is shown as a seq_1, and the mutant has mutation at least at the 174 th position of the amino acid sequence shown as the seq_1. Compared with the wild LbCAs12a protein, the mutant has SNP identification capability, and based on the CRISPR-Cas system designed by the mutant, the SNP in the genome can be identified within 30 minutes, and the sample preparation process of the system is very simple, so that cross contamination can be avoided, and the operation difficulty and detection cost can be reduced.
Description
Technical Field
The application belongs to the field of biology, and particularly relates to a mutant of a wild LbCAs12a protein and SNP detection application thereof.
Background
Single Nucleotide Polymorphisms (SNPs) mainly comprise single base transitions, base transversions, base deletions or base insertions, are the most common type of heritable variation in the human genome, with an average of one SNP per 1-1.9 kb. SNPs are involved in many biological processes including genetic diseases, tumorigenesis, drug metabolism, etc. Pharmacogenomics SNPs can be divided into four categories of SNPs related to drug absorption, drug transport, drug metabolism and drug excretion according to their functions, and are closely related to the sensitivity of individuals to drug treatment. The cytochrome P450 (CYP) family is the most important drug metabolizing enzyme, mediating multiple drug metabolisms. There are more than two thousand CYP single nucleotide polymorphisms reported so far, some of which have a significant impact on their enzymatic activity. For example, CYP2C9 is one of the key enzymes involved in the metabolism of the anticoagulant drug warfarin, and the use of warfarin requires an accurate personalized prescription that achieves a precise balance between over anticoagulation (thrombosis) and under anticoagulation (hemorrhage). Two common variants of CYP2C9, namely CYP2C9 x 2 (3608C > t) and CYP2C9 x 3 (42614 a > C), were found to result in reduced enzyme activity. Heterozygous or homozygous individuals carrying the above mutations are more sensitive to warfarin than normal individuals, and therefore they are at greater risk of bleeding during warfarin treatment and therefore require lower doses. For another example, CYP2C19 is a key metabolizing enzyme of clopidogrel. Clopidogrel is an effective anti-platelet aggregation drug, which is metabolized by CYP2C19 to produce 2-oxo-clopidogrel and finally metabolized into active thiol metabolites to play a role in inhibiting platelet aggregation. Patients carrying CYP2C19 (6815 > A) alleles in their genome have lost CYP2C19 enzymatic activity in their bodies, and therefore, treatment with clopidogrel can result in ineffective treatment, delayed disease, and bleeding risk. Therefore, rapid and accurate detection of key pharmacogenomics SNPs is critical for personalized medicine when using high risk drugs. Since CYP2C9 and CYP2C19 play an important role in the metabolic processes of various medicines such as warfarin, clopidogrel, phenytoin sodium, sinbocmod, valproate and the like, it is very important to develop a rapid and accurate detection method by taking CYP2C9 and CYP2C19 as detection targets.
Currently, various SNP detection methods have been developed, and can be broadly classified into two major categories, that is, electrophoresis-based methods and high-throughput identification methods. SNP detection based on electrophoresis, such as denaturing gradient gel electrophoresis, allele-specific PCR, cleavage amplification polymorphism sequence marking and the like, has the characteristics of long time consumption, low accuracy, and capability of identifying but not identifying specific SNP types. High throughput identification methods, such as DNA sequencing and high resolution melting, have the advantage of high accuracy, but they are also time consuming and relatively expensive.
CRISPR-Cas systems are widely used in the fields of genome editing and nucleic acid detection, etc., where type V and VI Cas proteins, such as Cas12a, cas12b, cas13a and Cas14, etc., are capable of initiating non-specific trans-cleavage upon generation of specific cis-cleavage, a feature which is the basis of CRISPR detection systems. These Cas proteins are able to recognize and cleave target DNA sequences under the guidance of crrnas, which in turn produce nonspecific trans-cleavage activity, beginning to cleave single-stranded DNA or RNA. By utilizing the above characteristics, amplification of the detection signal can be achieved by adding a reporter DNA or RNA sequence to the detection system. In the Cas proteins described above, cas13a and Cas14 are able to distinguish SNPs in RNA or single stranded DNA substrates, respectively. However, since amplification of RNA substrates and single-stranded DNA substrates requires a reverse transcription or single-stranded DNA generation step, the method cannot be applied to a one-step detection system; mutations are introduced in the crRNA of Cas12b, which can distinguish SNPs in double stranded DNA substrates, but their optimal cleavage temperature is 48 ℃, which greatly limits their compatibility with isothermal amplification techniques. Because the optimal reaction temperature of the recombinase polymerase amplification technology (RPA) is 37-42 ℃, the Cas12b must be matched with the loop-mediated isothermal amplification (LAMP), the optimal reaction temperature of the LAMP is 55-65 ℃, the change of the reaction temperature can reduce the cleavage activity of the Cas12b and prolong the incubation time, and finally the detection speed is reduced.
In contrast, cas12a can be perfectly matched with RPA, and Cas12a uses double-stranded DNA as a substrate, widely applied to nucleic acid detection. However, the need for TTTV-PAM and low specificity limit its use in SNP detection. Even if crRNA is extended, including adding additional TA-rich DNA sequences at the 3 'end of the crRNA, inserting nucleotides at the spacer (nucleotides at the 3' end of the crRNA and spacer) does not distinguish SNPs in the substrate well. Cas12a can distinguish SNPs in a two-step reaction by adding classical PAM sequences upstream of the target site and introducing additional mismatches on the crRNA during PCR amplification. Recent studies have disclosed a one-step nucleic acid detection system based on LbCas12a, termed "sPAMC", which shows very strong specificity and high sensitivity in SARS-CoV-2 detection. However, lbCas12a does not have the ability to discriminate SNPs, nor can it be applied to one-step SNP detection.
Disclosure of Invention
Aiming at the problems that the wild LbCAs12a protein in the prior art does not have the capability of distinguishing SNP and cannot be applied to the one-step SNP detection technology, the application carries out structural modification on the wild LbCAs12a protein to obtain a mutant with the capability of distinguishing SNP, and provides a one-step SNP detection system based on the mutant.
The technical scheme provided by the application is as follows:
in a first aspect, the present application provides a mutant of a wild-type LbCas12a protein, the amino acid sequence of the wild-type LbCas12a protein being as shown in seq_1, the mutant having a mutation at least at position 174 of the amino acid sequence shown in seq_1. The 174 th position of the amino acid sequence shown in seq_1 is Arg174 (abbreviated as R in the sequence), which is located in the REC domain of Cas12a, and interacts with crRNA, arg174 mutation possibly interfering with the substrate binding ability of Cas12 a-RNP. Preferably, amino acid 174 is mutated from R to K or A.
In some embodiments provided herein, the mutant further comprises a mutation at least one of position 538, 897, 945 of the amino acid sequence shown in seq_1. The 538 st, 897 th and 945 th sites of the amino acid sequence shown in the seq_1 are Lys538, lys897 and Lys945 respectively, the Lys897 and Lys945 are both positioned in a RuvC structural domain, the Lys538 is positioned in a WED structural domain, and mutation at any one of the positions can enhance the specificity of the mutant to identify SNP. Preferably, amino acid 538 is mutated from K to R, 897 is mutated from K to A, 945 is mutated from K to A. Further preferably, the mutants are any of R174A, R174K, K538R/R174K, K897A/R174A, K945A/R174A, and the mutants have stronger SNP distinguishing ability and the enzyme activity is not affected.
In a second aspect, the present application provides a fusion protein comprising a mutant of the wild-type LbCas12a protein described above, as well as other modifications.
In a third aspect, the present application provides a polynucleotide encoding a mutant of the wild-type LbCas12a protein described above or the fusion protein described above.
In a fourth aspect, the present application provides a vector comprising a polynucleotide as described above and a regulatory element operably linked thereto.
In a fifth aspect, the present application provides an engineered host cell comprising a mutant of the wild-type LbCas12a protein described above, or the fusion protein described above, or the polynucleotide described above, or the vector described above.
In a sixth aspect, the present application provides a CRISPR-Cas system or kit for one-step detection of SNPs on double-stranded DNA, comprising a mutant of the wild-type LbCas12a protein described above or the fusion protein described above and at least one gRNA;
the gRNA includes a mutant co-repeat sequence capable of binding the wild-type LbCas12a protein described above and a guide sequence crRNA capable of targeting a target sequence.
In a seventh aspect, the present application provides a composition comprising:
(i) A protein component selected from the group consisting of: mutants of the wild type LbCas12a protein described above or the fusion proteins described above;
(ii) A nucleic acid component which is a gRNA comprising a direct repeat sequence capable of binding to a mutant of the wild-type LbCas12a protein described above and a guide sequence capable of targeting a target sequence;
the protein component and the nucleic acid component are combined with each other to form a complex.
Compared with the prior art, the application has the following beneficial effects:
compared with the wild LbCAs12a protein, the mutant has SNP identification capability, and after the CRISPR-Cas system designed based on the mutant is not classical PAM and truncates crRNA, the SNP in a genome can be accurately identified within 30 minutes, and the sample preparation process of the system is very simple, so that cross contamination can be avoided, and the operation difficulty and detection cost can be reduced.
Drawings
FIG. 1 is a schematic diagram of a SeCas12 a-based SNP detection method. In a one-step reaction, RPA and Cas12a detection are reacted simultaneously. Crrnas targeting SNPs produce high fluorescence when reacted with DNA substrates with SNPs and weak fluorescence when reacted with incompletely paired substrates.
FIG. 2 is a schematic representation of crRNA design. Wherein crRNA G/681G or crRNAA/681A refers to crRNA that is perfectly complementary to CYP2C19 x 2681G or A alleles, respectively.
Fig. 3 is a summary heat map of endpoint (60 min) fluorescent signal values generated by LbCas12a candidate mutants on CYP2C19 x 2681G and a alleles. This experiment uses crRNA G/681G to detect CYP2C19 x 2681G (targeted) and a (non-targeted) alleles.
FIG. 4 is a summary heat map of endpoint (60 minutes) fluorescence signal values generated by rescreening the candidate proteins of FIG. 3. This experiment uses crRNAA/681A to detect CYP2C19 x 2681A and G alleles. The high and low fluorescence signals are represented in red and blue, respectively.
Fig. 5 demonstrates that CrRNA truncation can further enhance SNP discrimination capability of SeCas12a, wherein:
(A-B) SeCas12a (K538R/R174K) combined with crRNA of 19nt length produced the best SNP differentiation effect. This experiment used crRNAA/42614A and crRNA C/42614C to distinguish between CYP2C9 x 342614A and C alleles.
(A) Real-time fluorescence curves for four LbCas12a RNPs. The experiment was read every 2 minutes for 1 fluorescence signal (λex=485 nm; λem=528 nm). (the dashed line is the mean ± standard deviation value, n=3).
(B) Bar graph of endpoint (30 min) fluorescence signal values generated for each LbCas12a RNP in panel (a). (n=3, mean ± standard deviation).
(C) In vitro cis-cleavage activity of each RNP in Panel (A).
(D) The cis-cleavage kinetics curves of LbCas12a and SeCas12a are shown.
(E) Shows the correlation of cis-cleavage activity with signal to noise ratio of one-step method.
Fig. 6 demonstrates the advantages of a single-step SNP detection system based on SeCas12a, wherein:
(A) Classical PAM (grey) and non-classical PAM (blue) distribution of LbCas12a in the human genome.
(B) Real-time fluorescence curves generated by non-classical PAM (5 '-TCCA-3') and classical PAM (5 '-TTTA-3') in a one-step SNP detection reaction. The experiment used crRNA A/42614A (19 nt) and crRNA C/42614C (19 nt) to detect CYP2C9 x 342614A and C alleles. (n=3, mean ± standard deviation).
(C) Schematic representation of the position of SNP sites in crRNA.
(D) Fluorescence signal of M1-M19. The position of the SNP site in the crRNA affects the specificity of the one-step SNP detection. The experiment was based on crRNAA/42614A, with sequential mutations of bases in crRNAA, so that SNPs are at different positions in the crRNA.
(E) Histogram of endpoint fluorescence values (60 th minute) in panel (D).
(F) The single-step SNP detection system is not limited to the type of base mutation. The histogram is statistical information of the endpoint fluorescence values (60 th minute). The experiment used crRNAA/42614A. The read interval of the fluorescent signal was 2 minutes (λex=485 nm; λem=528 nm). Data are mean ± standard deviation, (n=3).
Fig. 7 uses a response based on SeCas12a to detect human pharmacogenomic SNPs, wherein:
(A) CYP2C9 x 342614A and C alleles in human samples were detected using truncated crRNA. The experiment used crRNAA/42614A (19 nt) and crRNAC/42614C (19 nt), with a sample size of 3.NC is a negative control, without any DNA substrate. Data are mean ± standard deviation. (n=3).
(B) CYP2C 19X 2681G and A alleles in human samples were detected using full-length crRNA. The experiment used crRNAG/681G (20 nt) and crRNAA/681A (20 nt), with a sample size of 6.NC is a negative control, without any DNA substrate. Data are mean ± standard deviation, (n=3).
Figure 8 demonstrates the specificity and activity of Cas12a, wherein:
(A) crRNA screening results for CYP2C19 x 2681G and a alleles. The high and low fluorescence signals are displayed in red and blue, respectively.
(B) Wild type LbCas12a protein does not possess SNP discrimination capability. The experiment used full length or truncated crRNAA/42614A.
(C-D) demonstrates trans-cleavage activity of each candidate mutant of LbCAs12a in FIG. 3. The experiment used crRNAG/681G (FIG. 8C) and crRNAA/681A (FIG. 8D).
Detailed Description
The method comprises the steps of modifying wild LbCAs12a protein by taking a crystal structure as a guide, constructing a mutant series of the wild LbCAs12a protein, screening out mutant SeCas12a with better specificity and weaker activity, expanding one-step nucleic acid detection to one-step SNP detection by using the mutant, designing a simplified SNP detection system based on the SeCas12a, enabling the SNP detection and RPA amplification mediated by the Cas12a to be carried out simultaneously in the same reaction system, adding allele-specific crRNA in each independent reaction, and judging the SNP type corresponding to a substrate DNA sequence by detecting fluorescent reading of each allele-specific (figure 1). The SNP detection system uses non-classical PAM in the Cas12a system to perform ultra-rapid nucleic acid detection with higher sensitivity, reproducibility and flexibility. The sample genome of the Cas12a system has a huge number of non-classical PAM, so that the detection range of the sample genome on the genome is greatly widened. Both classical and non-classical PAM perform well in single step reactions based on SeCas12a, which allows the present application to detect SNPs at almost any location in the genome without suffering from PAM. In addition, for different targets, the detection effect can reach the optimal state by adjusting the length of crRNA. Thus, the SNP detection system of the present application can detect SNPs distributed at almost any position of the genome.
The present application is further described below in connection with the examples, which are provided solely for better illustration of the technical solution of the present application and are not intended to limit the claims. The present application is not limited to the specific examples and embodiments described herein. Further modifications and improvements may readily be made by those skilled in the art without departing from the spirit and scope of the present application, and are intended to fall within the scope of the present application.
Examples
(1) Mutant design of wild type LbCas12a protein:
the wild type LbCas12a protein is reported to be unable to recognize single nucleotide mismatches in the substrate.
Applicants speculate that the strength of binding between Cas12a-RNP and the substrate may be critical for its specificity. To verify this hypothesis, the present application mutated amino acids responsible for crRNA binding and DNA recognition, such as Ser168, arg174, asn260, ser286, lys897, ile896, gln944, lys945, phe983, lys984 and Arg883 in the helical domain, in the REC1 domain of the wild-type LbCas12a protein, to alanine a or lysine K, respectively, to alter binding affinity. The amino acids in the wild type LbCas12a protein (Asp 156, asn260, gly532 and Lys538, respectively) were also mutated in the present application, and the mutation is shown in table 1.
The amino acid sequence of the wild-type LbCas12a protein is shown as seq_1 (candidate mutation sites are respectively 156 th, 168 th, 174 th, 260 th, 286 th, 532 th, 538 rd, 883 rd, 897 th, 896 th, 944 th, 945 th, 983 rd and 984 th positions underlined):
MSKLEKFTNCYSLSKTLRFKAIPVGKTQENIDNKRLLVEDEKRAEDYKGVKKLLDRYYLSFINDVLHSIKLKNLNNYISLFRKKTRTEKENKELENLEINLRKEIAKAFKGNEGYKSLFKKDIIETILPEFLDDKDEIALVNSFNGFTTAFTGFFDNRENMFSEEAKSTSIAFRCINENLTRYISNMDIFEKVDAIFDKHEVQEIKEKILNSDYDVEDFFEGEFFNFVLTQEGIDVYNAIIGGFVTESGEKIKGLNEYINLYNQKTKQKLPKFKPLYKQVLSDRESLSFYGEGYTSDEEVLEVFRNTLNKNSEIFSSIKKLEKLFKNFDEYSSAGIFVKNGPAISTISKDIFGEWNVIRDKWNAEYDDIHLKKKAVVTEKYEDDRRKSFKKIGSFSLEQLQEYADADLSVVEKLKEIIIQKVDEIYKVYGSSEKLFDADFVLEKSLKKNDAVVAIMKDLLDSVKSFENYIKAFFGEGKETNRDESFYGDFVLAYDILLKVDHIYDAIRNYVTQKPYSKDKFKLYFQNPQFMGGWDKDKETDYRATILRYGSKYYLAIMDKKYAKCLQKIDKDDVNGNYEKINYKLLPGPNKMLPKVFFSKKWMAYYNPSEDIQKIYKNGTFKKGDMFNLNDCHKLIDFFKDSISRYPKWSNAYDFNFSETEKYKDIAGFYREVEEQGYKVSFESASKKEVDKLVEEGKLYMFQIYNKDFSDKSHGTPNLHTMYFKLLFDENNHGQIRLSGGAELFMRRASLKKEELVVHPANSPIANKNPDNPKKTTTLSYDVYKDKRFSEDQYELHIPIAINKCPKNIFKINTEVRVLLKHDDNPYVIGIDRGERNLLYIVVVDGKGNIVEQYSLNEIINNFNGIRIKTDYHSLLDKKEKERFEARQNWTSIENIKELKAGYISQVVHKICELVEKYDAVIALEDLNSGFKNSRVKVEKQVYQKFEKMLIDKLNYMVDKKSNPCATGGALKGYQITNKFESFKSMSTQNGFIFYIPAWLTSKIDPSTGFVNLLKTKYTSIADSKKFISSFDRIMYVPEEDLFEFALDYKNFSRTDADYIKKWKLYSYGNRIRIFRNPKKNNVFDWEEVCLTSAYKELFNKYGINYQQGDIRALLCEQSDKAFYSSFMALMSLMLQMRNSITGRTDVDFLISPVKNSDGIFYDSRNYEAQENAILPKNADANGAYNIARKVLWAIGQFKKAEDEKLDKVKIAISNKEWLEYAQTSVKH。
TABLE 1 mutation of wild type LbCAs12a protein according to the present application
(2) Design and screening of CrRNA
The design and screening of crrnas is the basis of detection reactions, and crrnas targeting two clinically relevant targets, CYP2C9 x 3 (424 a > C) and CYP2C19 x 2 (6811 g > a), were first designed and screened. And (3) comparing and analyzing the intensity of fluorescent signals generated by the allele specific crRNA and the matched genotype or the unmatched genotype, and screening crRNA with higher specific signals and lower nonspecific signals for subsequent experiments.
Table 2 42 candidate crrnas designed for CYP2C19 x 2 sites
Of the 42 candidate crrnas designed for the CYP2C19 x 2 locus, crRNA # 17 and crRNA # 30 had the highest specificity for their respective genotypes (fig. 8A) and were used for further optimization.
(3) Mutant screening of wild type LbCas12a protein
The present application performed a first round of screening with crRNA # 17 targeting the G allele in CYP2C19 x 2 (6811G > a) for a series of mutants of wild-type LbCas12a protein constructed in table 1 (fig. 2). As shown in FIG. 3, the mutants containing the mutation site of R174A, R174K, K538R/R174K, K897A/R174A or K945A/R174A had stronger SNP distinguishing ability than the wild type LbCAs12a protein, and the enzyme activity was not affected. Of the above mutants, the specificity of R174A and R174K for recognition of SNPs was most prominent, indicating that Arg174 is associated with the specificity of LbCas12 a. Applicants believe that Arg174 is located in the REC domain of Cas12a, and that the interaction with crRNA, arg174 mutation, may interfere with the substrate binding capacity of Cas12 a-RNP. Arg174 is mutated in combination with other amino acids in the present application in order to further increase its specificity. Among them, three mutations containing two mutation sites of K538R/R174K, K897A/R174A and K945A/R174A showed higher specificity, while three mutants of K538R, K897A, K945A having only one mutation site had poor specificity, which further highlighted the importance of mutation site Arg 174. The mutant K538R/R174K containing two mutation sites is finally selected as the optimal mutant for identifying SNP, because the mutant has good stability on different targets.
(4) Mutant targeting stability screening:
to determine whether the 5 mutants screened in the first round (R174A, R174K, K538R/R174K, K897A/R174A, K945A/R174A) were stable in function when targeting the a allele in CYP2C19 x 2, a second round of screening was performed on these 5 mutants using crRNA #30 (fig. 2). The experimental results show that of these 5 mutants, only K538R/R174K showed higher specificity in targeting the a allele in CYP2C19 x 2, i.e. a very high fluorescent signal was generated in targeting the a allele in CYP2C19 x 2, whereas only a weak background fluorescence was generated in targeting the G allele (fig. 4).
(5) The effect of crRNA # 17 and crRNA # 30 on the enzymatic activity of the 5 mutants screened in the first round was verified:
to assess whether the enzymatic activity of the 5 mutants screened in the first round was affected, a simple trans-cleavage assay was performed in which the reaction system did not contain the RPA amplification component. In this experiment, crrna# 17 and crrna# 30 targeting CYP2C19 x 2 (681) G or a alleles and their corresponding substrate DNA were used in the present application (fig. 8C and 8D). Experimental results show that the enzyme activity of the 5 mutants screened in the first round is reduced to different degrees while the specificity is improved. The K538R/R174K mutant with the highest specificity has the weakest enzyme activity and stronger SNP distinguishing capability, and is named as SeCas12 (sensitive Cas12 a).
(6) The truncated crRNA further enhances the sensitivity of the SeCas12 a:
to explore whether crRNA truncation can further improve the specificity of the single-step SNP detection system based on SeCas12a, the present application uses crRNAA or crRNAC targeting the CYP2C9 x 3 (42614) a or C allele. Because of the limited number of PAMs in the CYP2C9 x 3 (424 a > C) target, only one crRNA was available, and there was no screening room, the present application performed a series of truncations of crrnas targeting this SNP site, and compared the specificity of crRNA truncations (fig. 8B). Experiments show that crRNA truncation improves crRNA specificity to some extent, but the overall discrimination effect is not ideal, so crRNA truncation alone cannot be used as a main means of discriminating SNPs.
Table 3 candidate crrnas designed for CYP2C9 x 3 in the present application
By comparing the endpoint fluorescence signal values by analysis, it was found that only crRNAC of length 18nt, when used in combination with SeCas12a, did not generate a sufficiently strong fluorescence signal, and crRNAC of length 19nt, when used in combination with SeCas12a, had the highest specificity of the SeCas12a detection system (fig. 5A). In contrast, the CRISPR-Cas system, with a length of 19nt crRNA C in combination with the wild-type LbCas12a protein, was able to target the a allele but produced a large amount of non-specific fluorescent signal (fig. 5A). The present application also found that crRNAA shows high specificity at all three lengths (fig. 5B).
(7) One-step SNP detection system design based on SeCas12a
Studies have shown that dynamic balance between CRISPR activity and RPA amplification is critical for one-step detection reactions. In one aspect, CRISPR detection requires amplification of large amounts of target DNA by RPA to generate a sufficiently strong fluorescent signal; on the other hand, CRISPR detection systems require cleavage of target DNA to generate a fluorescent signal. To achieve this equilibrium, it is necessary to down-regulate CRISPR kinetics in order to achieve RPA-mediated mass amplification of target sequences at the early stages of the one-step detection reaction. Whereas in SNP detection, the targeted and non-targeted DNA sequences differ only by one nucleotide, so a more stringent balance of CRISPR dynamics between targeted and non-targeted is required.
The cis-cleavage activity of SeCas12a was quantified with crRNAA and crRNA C (FIG. 5C). crRNAA exhibits weaker cis-cleavage activity when used in combination with wild-type Cas12a protein or SeCas12 a; whereas crRNAC exhibits higher cis-cleavage activity when paired with SeCas12a (fig. 5C). Furthermore, crrnas of 18nt length exhibited very weak or even no cis-cleavage activity when used in combination with wild-type Cas12a protein or SeCas12a (fig. 5C). This may explain why crrnas of 18nt length do not produce sufficient fluorescent signals. These data indicate that only when cis-cleavage activity is low to a certain threshold, it specifically cleaves perfectly matched substrates and not incompletely matched substrates, thereby selectively generating a fluorescent signal.
Taken together, crRNA length is critical in single-step SNP detection based on SeCas12 a. For target sites exhibiting strong cis-cleavage activity, a truncated crRNA (19 nt) is required, whereas target sites exhibiting weak cis-cleavage activity require crrnas of 20nt in length.
(8) Single-step SNP detection system based on SeCas12a
The present application contemplates a single step SNP detection system based on SeCas12a in which the present application uses non-classical PAM instead of classical PAM. Thus, the one-step SNP detection system can be used as a generalized platform for detecting almost any target in the genome. Statistical data indicate that the number of non-classical PAMs of LbCas12a in the human genome is 4.62 times that of classical PAM (fig. 6A).
To verify whether classical PAM is suitable for use in a single-step SNP detection system based on SeCas12a, the present application mutates non-classical PAM (TCCA) of crRNAA or crRNA C targeting the CYP2C9 x 3 (42614 as shown in seq_50) a or C allele to classical PAM (TTTA) as a substrate for the single-step SNP detection system. The amino acid sequence of seq_50 is:
tgtgcatctgtaaccatcctctctttaagtttgcatatacttccagcactataatttaaatttataatgatgtttggataccttcatgattcatatacccctgaattgctacaacaaatgtgccatttttctccttttccatcagtttttacttgtgtcttatcagctaaagtccaggaagagattgaacgtgtgattggcagaaaccggagcccctgcatgcaagacaggagccacatgccctacacagatgctgtggtgcacgaggTCCAgagatacattgaccttctccccaccagcctgccccatgcagtgacctgtgacattaaattcagaaactatctcattcccaaggtaagtttgtttctcctacactgcaactccatgttttcgaagtccccaaattcatagtatcatttttaaacctctaccatcaccgggtgagagaagtgcataactcatatgtatggcagtttaactggactttctcttgtttggtacctcgcgaatgcatctagatatcggatcccgggcccgtcgactgcagaggcctgcatgcaagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagcta, note: uppercase TCCA is a non-classical PAM, underlined is the spacer region.
It was found that 19nt CrRNAA showed similar specificity on substrates containing classical or non-classical PAM, whereas 19nt crRNAC produced a background signal of a certain intensity when targeting substrates containing classical PAM (fig. 6B), indicating that PAM selection had to be tested and screened separately for each crRNA to meet its kinetic requirements.
Next, the present application determines whether the position of a SNP within a spacer affects the detection effect of a one-step detection reaction by sequentially single mutating the nucleotides within the spacer region on the substrate DNA. Wherein M0 represents no mutation, and M1 to M19 represent mutations at the specified positions (FIG. 6C). As shown in FIG. 6D, in addition to M18 and M19 producing high fluorescence signals, M1 through M7 and M14-M17 each produce weak fluorescence signals distinguishable from the wild type substrate (M0), while M8 through M13 produce background level signals. In summary, the one-step response based on SeCas12a can distinguish mutations in the PAM proximal region from the middle spacer, but not in the PAM distal region. In short, in the design of crrnas, a distinct distinction of specific fluorescent signals from background signals can be achieved as long as SNPs are in the 1-13 position (from the PAM side). As shown in table 4:
TABLE 4 mutation site of M0-M19 crRNA sequence (19 nt)
Note that: underlined are mutation sites.
To explore whether a single-step SNP detection system based on SeCas12a was able to detect base transitions and base transversions, the present application mutated the CYP2C9 x 3 (42614) a allele to C, G and T, respectively, and conducted SNP detection experiments. The results show that both crRNAA and crRNAC can effectively distinguish base transitions or base transversions (fig. 6E). Quantitative analysis of endpoint fluorescence signals also demonstrated that crRNAA produced significantly higher fluorescence signals on specific targets (a) than on C, G and T targets. Likewise, crRNAC produced a very high fluorescent signal at specific target (C), while only background level fluorescent signal was produced at A, G and T targets (fig. 6E). In summary, the single-step SNP detection system based on SeCas12a can utilize both classical and non-classical PAM and is hardly limited by mutation positions and mutation types.
(9) Detection of pharmacogenomic SNPs using a single-step SNP detection system based on SeCas12a
CYP2C9 x 3 (424A > C) and CYP2C19 x 2 (6811G > A) in a human sample are detected by the one-step SNP detection system based on the SeCas12 a. Crrnas a and C of length 19nt were used to detect CYP2C9 x 342614a and C alleles and crrnas # 17 and #30 were used to detect CYP2C19 x 2681G and a alleles.
TABLE 5 RPA primers used in experiments
The experimental procedure was as follows:
s1, preparing a sample: human oral epithelial cells were gently scraped off into 500. Mu.L of PBS buffer and centrifuged at 300rcf for 5 min (10 min at 200 g). The supernatant was discarded, and 100ul of PBS (400. Mu.L of supernatant discarded) and proteinase K (final concentration 200. Mu.g/ml) were added. Digestion at 55℃for 60 min and heating at 80℃for 10min deactivates proteinase K.
S2, preparing a reaction system.
Adding 30 mu LABuffer,10 mu L of non-ribozyme water, 4 mu L of forward RPA primer and 4 mu L of reverse RPA primer into each tube of RPA powder (Anpu future), shaking, mixing, standing at room temperature for 2min to dissolve the powder; adding 9 mu L of dissolved RPA reagent, 3 mu L of seCas12a (1 mu M), 3 mu L of crRNA (1 mu M), 4 mu L of ssDNAreport (4 mu M,5 '-TTATT-3'), shaking for 10s, mixing uniformly, and standing at room temperature for 10min to incubate to form RNP; sequentially adding 2 mu L of samples and 2.5 mu LB buffer, rapidly sealing, and immediately placing in an enzyme-labeled instrument for detection.
S3, detecting fluorescence by using an enzyme-labeled instrument. Fluorescence values (excitation light 485nm, emission light 528 nm) were read every minute at 37℃to generate a kinetic profile.
In the above experiments, the oral epithelial cells of the volunteers were rapidly dissolved into buffer solution and used as detection templates directly without purification. The corresponding SNP was accurately detected by the SeCas12 detection system within 30 minutes in 3 samples corresponding to the CYP2C9 x 3 target (fig. 7A). In 6 samples of the present application using crRNA # 17 and crRNA # 30 to detect CYP2C19 x 2681G and a alleles, crRNA # 17 and crRNA # 30 each successfully produced allele-specific fluorescent signals within 30 minutes (fig. 7B). In summary, the one-step SNP detection system based on SeCas12a can accurately detect two pharmacogenomic SNPs in a crude solution of a human sample.
While the preferred embodiments of the present application have been described, it is of course not intended to limit the scope of the claims, and it should be noted that modifications and variations could be made by persons skilled in the art without departing from the principles of the present application, and these modifications and variations are also considered to be within the scope of the present application.
Claims (10)
1. A mutant of a wild-type LbCas12a protein, the amino acid sequence of which is shown in seq_1, characterized in that: the mutant has a mutation at least at position 174 of the amino acid sequence shown in seq_1.
2. The mutant of wild-type LbCas12a protein according to claim 1, characterized in that: the mutant also has a mutation at least one of 538, 897 and 945 in the amino acid sequence shown in seq_1.
3. A fusion protein comprising a mutant and other modified portions of the wild-type LbCas12a protein of claim 1 or 2.
4. A polynucleotide, characterized in that: a mutant encoding the wild-type LbCas12a protein of claim 1 or 2 or the fusion protein of claim 3.
5. A vector comprising the polynucleotide of claim 4 operably linked to regulatory elements.
6. An engineered host cell comprising a mutant of the wild-type LbCas12a protein of claim 1 or 2, or the fusion protein of claim 3, or the polynucleotide of claim 4, or the vector of claim 5.
7. A CRISPR-Cas system or kit for one-step detection of SNPs on double-stranded DNA, characterized in that the CRISPR-Cas system or kit comprises a mutant of the wild-type LbCas12a protein of claim 1 or 2 or the fusion protein of claim 3 and at least one gRNA;
the gRNA comprises a cognate repeat sequence capable of binding to a mutant of the wild-type LbCas12a protein of claim 1 and a guide sequence crRNA capable of targeting a target sequence.
8. The CRISPR system or kit for the one-step detection of SNPs on double-stranded DNA according to claim 7, wherein: the crRNA has a sequence length of 19nt.
9. The CRISPR system or kit for the one-step detection of SNPs on double-stranded DNA according to claim 7, characterized in that: the SNPs are located 1 st to 13 th nt on the double-stranded DNA from the PAM side.
10. A composition, characterized in that it comprises:
(i) A protein component selected from the group consisting of: a mutant of the wild-type LbCas12a protein of claim 1 or 2 or the fusion protein of claim 3;
(ii) A nucleic acid component which is a gRNA comprising a direct repeat sequence capable of binding to a mutant of the wild-type LbCas12a protein of claim 1 or 2 and a guide sequence capable of targeting a target sequence;
the protein component and the nucleic acid component are bound to each other to form a complex.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211514174.0A CN116286734B (en) | 2022-11-29 | 2022-11-29 | Mutant of wild LbCAs12a protein and SNP detection application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211514174.0A CN116286734B (en) | 2022-11-29 | 2022-11-29 | Mutant of wild LbCAs12a protein and SNP detection application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116286734A true CN116286734A (en) | 2023-06-23 |
CN116286734B CN116286734B (en) | 2024-04-02 |
Family
ID=86827509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211514174.0A Active CN116286734B (en) | 2022-11-29 | 2022-11-29 | Mutant of wild LbCAs12a protein and SNP detection application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116286734B (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017184786A1 (en) * | 2016-04-19 | 2017-10-26 | The Broad Institute Inc. | Cpf1 complexes with reduced indel activity |
CA3026055A1 (en) * | 2016-04-19 | 2017-10-26 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
CN109957569A (en) * | 2017-12-22 | 2019-07-02 | 中国科学院遗传与发育生物学研究所 | Base editing system and method based on CPF1 albumen |
CN110878343A (en) * | 2019-12-03 | 2020-03-13 | 国家卫生健康委科学技术研究所 | Cpf1 kit for quickly detecting genetic deafness pathogenic gene SLC26A4 mutation and detection method thereof |
WO2020142754A2 (en) * | 2019-01-04 | 2020-07-09 | Mammoth Biosciences, Inc. | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection |
WO2021076682A1 (en) * | 2019-10-17 | 2021-04-22 | Pairwise Plants Services, Inc. | Variants of cas12a nucleases and methods of making and use thereof |
CN112980933A (en) * | 2020-12-30 | 2021-06-18 | 南方科技大学 | SNP (Single nucleotide polymorphism) typing detection method based on CRISPR-Cas (clustered regularly interspaced short palindromic repeats) system and application thereof |
CN113136376A (en) * | 2021-05-26 | 2021-07-20 | 武汉大学 | Cas12a variant and application thereof in gene editing |
CN114214348A (en) * | 2021-11-16 | 2022-03-22 | 河南农业大学 | Crispr/LbCas12a mutant protein applied to nucleic acid detection and preparation method and application thereof |
CN115335536A (en) * | 2021-01-08 | 2022-11-11 | 武汉大学 | Compositions and methods for point-of-care nucleic acid detection |
-
2022
- 2022-11-29 CN CN202211514174.0A patent/CN116286734B/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017184786A1 (en) * | 2016-04-19 | 2017-10-26 | The Broad Institute Inc. | Cpf1 complexes with reduced indel activity |
CA3026055A1 (en) * | 2016-04-19 | 2017-10-26 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
CN110382692A (en) * | 2016-04-19 | 2019-10-25 | 博德研究所 | Novel C RISPR enzyme and system |
CN109957569A (en) * | 2017-12-22 | 2019-07-02 | 中国科学院遗传与发育生物学研究所 | Base editing system and method based on CPF1 albumen |
WO2020142754A2 (en) * | 2019-01-04 | 2020-07-09 | Mammoth Biosciences, Inc. | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection |
WO2021076682A1 (en) * | 2019-10-17 | 2021-04-22 | Pairwise Plants Services, Inc. | Variants of cas12a nucleases and methods of making and use thereof |
CN110878343A (en) * | 2019-12-03 | 2020-03-13 | 国家卫生健康委科学技术研究所 | Cpf1 kit for quickly detecting genetic deafness pathogenic gene SLC26A4 mutation and detection method thereof |
CN112980933A (en) * | 2020-12-30 | 2021-06-18 | 南方科技大学 | SNP (Single nucleotide polymorphism) typing detection method based on CRISPR-Cas (clustered regularly interspaced short palindromic repeats) system and application thereof |
CN115335536A (en) * | 2021-01-08 | 2022-11-11 | 武汉大学 | Compositions and methods for point-of-care nucleic acid detection |
CN113136376A (en) * | 2021-05-26 | 2021-07-20 | 武汉大学 | Cas12a variant and application thereof in gene editing |
CN114214348A (en) * | 2021-11-16 | 2022-03-22 | 河南农业大学 | Crispr/LbCas12a mutant protein applied to nucleic acid detection and preparation method and application thereof |
Non-Patent Citations (4)
Title |
---|
CIURKOT, K: "DNase-dead CRISPR-associated endonuclease Cas12a [synthetic construct]", GENBANK DATABASE, pages 56480 * |
HONG-XIA ZHANG等: "Cas12a-based one-pot SNP detection with high accuracy", CELL INSIGHT, vol. 2, no. 2, pages 100080 * |
刘茹等: "LbCas12a蛋白的原核表达及活性检测", 中国畜牧兽医, vol. 49, no. 5, pages 1621 - 1629 * |
张红霞: "TRIM27调控IL-6诱导的STAT3激活的分子机制及其在肿瘤发生中的作用", 中国博士学位论文全文数据库(电子期刊)医药卫生科技辑, no. 6, pages 072 - 2 * |
Also Published As
Publication number | Publication date |
---|---|
CN116286734B (en) | 2024-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10515714B2 (en) | Methods for accurate sequence data and modified base position determination | |
White et al. | Digital PCR provides sensitive and absolute calibration for high throughput sequencing | |
Ota et al. | Single nucleotide polymorphism detection by polymerase chain reaction-restriction fragment length polymorphism | |
US6165714A (en) | Devices and methods for detecting nucleic acid analytes in samples | |
Demidov | Rolling-circle amplification in DNA diagnostics: the power of simplicity | |
CN105018548B (en) | Kit for modification of nucleic acids | |
EP3115468B1 (en) | Increasing confidence of allele calls with molecular counting | |
US10072260B2 (en) | Target enrichment of randomly sheared genomic DNA fragments | |
Zhang et al. | Lighting up single-nucleotide variation in situ in single cells and tissues | |
JP7232643B2 (en) | Deep sequencing profiling of tumors | |
WO2020215652A1 (en) | Detection technology system for enriching low-abundance dna mutation on the basis of nuclease-coupled pcr principle and application thereof | |
CN104962609B (en) | Detect primer, kit and its PCR method of CYP2C9 and VKORC1 gene pleiomorphisms | |
CN1318606C (en) | Methods and compositions for detecting targets | |
CN104450869B (en) | Dideoxynucleoside modified primer method, reaction system and application thereof in mutation detection | |
CN110886021A (en) | Method for constructing single cell DNA library | |
Jelinek et al. | DREAM: a simple method for DNA methylation profiling by high-throughput sequencing | |
JP2010535501A (en) | Methods to identify individuals at risk of thiopurine drug resistance and thiopurine drug intolerance | |
KR20220130592A (en) | Highly sensitive methods for accurate parallel quantification of nucleic acids | |
CN108359723B (en) | Method for reducing deep sequencing errors | |
Liu et al. | Development of a POCT detection platform based on a locked nucleic acid-enhanced ARMS-RPA-GoldMag lateral flow assay | |
CN116286734B (en) | Mutant of wild LbCAs12a protein and SNP detection application | |
Luo et al. | Two-point-one-line modularized strategy combined with Holliday-junction button probes for multiloci SNPs long-range distribution analysis | |
Taylor et al. | The polymerase chain reaction: new variations on an old theme | |
CN107287283A (en) | A kind of the high flux detection kit and its application method of many SNP sites related to children's susceptibility to disease | |
CN114277114B (en) | Method for adding unique identifier in amplicon sequencing and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |